Showing 65 results for "superoxide dismutase 1"

Study Describes New Compounds With Potential to Treat ALS

Newly developed compounds derived from ebselen could be used to treat some types of amyotrophic lateral sclerosis (ALS), a recent study suggests. The study, “Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis,” was published in EBioMedicine. About a fifth of familial…

Single Injection of RNA Therapy Blocks Degeneration, Prevents Disease Progression in Mice Models of Familial ALS

A single spinal injection of an investigational RNA therapy blocked motor neuron degeneration and saved motor function in animal models of familial amyotrophic lateral sclerosis (ALS) linked to SOD1 mutations, a study  reports. Giving the treatment — a virus-delivered gene-silencer targeting the SOD1 gene —  before the onset of…

Neuropore’s NPT520-34 Given FDA’s Orphan Drug Designation for ALS Treatment

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to NPT520-34, an investigational anti-neuroinflammatory molecule, for the treatment of amyotrophic lateral sclerosis (ALS), Neuropore Therapies announced. “We are very pleased with receiving this orphan drug designation from the FDA’s Office of Orphan Product Development for NPT520-34…

Klotho Protein Protects Brains of ALS Mice, Study Suggests

The klotho protein may have brain-protecting effects in amyotrophic lateral sclerosis (ALS), according to a study in mice that may become a basis for developing new therapies. The study, “Klotho Is Neuroprotective in the Superoxide Dismutase (SOD1G93A) Mouse Model of ALS,” was published in the Journal…

Telbivudine

Telbivudine is a synthetic nucleoside developed by Novartis and approved by the U.S. Food and Drug Administration under the brand name Tyzeka for the treatment of hepatitis B. A recent study identified telbivudine as a potential treatment for amyotrophic lateral sclerosis (ALS). How…

Gleevec (Imatinib Mesylate)

Gleevec (imatinib mesylate), marketed by Novartis, is an oral medication approved by the U.S. Food and Drug Administration (FDA) for treating certain types of cancer, such as leukemia and gastrointestinal stromal tumors (GISTs). Gleevec also is being investigated in preclinical studies as a potential treatment for…